Skip to Content


Prospective Grant of an Exclusive License: Human Papillomavirus 16 E2 and E6 Peptides for Cervical Cancer Vaccine Development

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


National Institutes of Health, HHS.




This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the inventions embodied in:

NIH Ref. No.Patent application No.Filing dateIssued patent no. (if any)
NIH Ref. E-126-2001/0-AU-062002258614March 22, 20022002258614
NIH Ref. E-126-2001/0-CA-042441947March 22, 2002
NIH Ref. E-126-2001/0-EP-052728570.9March 22, 2002
NIH Ref. E-126-2001/0-PCT-02PCT/US02/09261March 22, 2002(Expired)
NIH Ref. E-126-2001/0-US-0160/278,520March 23, 2001(Expired)
NIH Ref. E-126-2001/0-US-0310/472,661September 23, 20037,189,513
NIH Ref. E-126-2001/0-US-0711/685,632March 13, 20077,507,538
NIH Ref. E-155-2005/0-US-0160/671,463April 15, 2005(Expired)
NIH Ref. E-155-2005/1-US-0160/680,000May 12, 2005(Expired)
NIH Ref. E-155-2005/2-US-0160/724,783October 11, 2005(Expired)
NIH Ref. E-155-2005/3-AU-042006236905April 11, 2006
Start Printed Page 42531
NIH Ref. E-155-2005/3-CA-052604909April 11, 2006
NIH Ref. E-155-2005/3-EP-03 (CH, DE, FR, GB, and IE)6749659.6April 11, 20071877087
NIH Ref. E-155-2005/3-PCT-01PCT/US2006/1331April 11, 2006(Expired)
NIH Ref. E-155-2005/3-US-0211/918,557October 11, 20067,691,579

to Georgia Health Sciences University Research Institute, Inc. having a principal place of business in Augusta, Georgia.

The United States of America is an assignee to the patent rights of these inventions.

The contemplated exclusive license may be in a field of use directed to cervical cancer vaccines.


Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before August 15, 2013 will be considered.


Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Michael Shmilovich, Esq, CLP, Senior Licensing and Patent Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-5019; Facsimile: (301) 402-0220; Email: A signed confidential disclosure agreement may be required to receive copies of patent applications assuming it has not already issued or been published under either the publication rules of either the US Patent and Trademark Office or World Intellectual Property Organization.

End Preamble Start Supplemental Information


NIH Ref. No. E-155-2005/0-3 (as Above)

The invention pertains primarily to CD8+ T cell epitopes from HPV16 E2. These epitopes generated from amino acid positions 69-77 (ALQAIELQL) and 138-147 (YICEEASVTV) bind to HLA.A2 and elicit CD8+ cytotoxic T cell responses that lyse tumor cells of low-grade cervical neoplasia (wart).

NIH Ref. No. E-126-2001/0 (as Above)

Immunogenic peptides from the HPV-18E6 (X1 KLPDLCTELX2;, wherein X2 and X1 are peptides of 0-11 amino acids in length comprising contiguous HPV 18 E6 amino acid sequences) protein that comprise class I restricted T cell epitopes and methods of administering the same. The HPV-18E6 peptide cross-reacts immunologically with both HPV type 16 and HPV type 18 with higher affinity than most common human lymphocyte antigen (HLA), HLA-A2 than the homologous peptide from HPV 16. E6 peptide vaccines are potentially prophylactic or therapeutic for cervical cancer, other genital cancers, head and neck cancers, and upper digestive tract cancers. It could also be potentially used in the treatment of patients presenting with pre-malignant cervical disease, especially in underdeveloped countries with no access to surgical treatment or to completely avoid surgical treatment.

The prospective exclusive license will be royalty-bearing and comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless, within thirty (30) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Start Signature

Dated: July 9, 2013.

Richard Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

End Signature End Supplemental Information

[FR Doc. 2013-16949 Filed 7-15-13; 8:45 am]